Anti-CDKN2A/p14ARF antibody (ab3642)
Key features and details
- Rabbit polyclonal to CDKN2A/p14ARF
- Suitable for: IHC-P, ICC/IF
- Reacts with: Human
- Isotype: IgG
Overview
-
Product name
Anti-CDKN2A/p14ARF antibody
See all CDKN2A/p14ARF primary antibodies -
Description
Rabbit polyclonal to CDKN2A/p14ARF -
Host species
Rabbit -
Tested Applications & Species
See all applications and species dataApplication Species ICC/IF Human
-
Immunogen
Synthetic peptide within Human CDKN2A/p14ARF (C terminal). The exact sequence is proprietary.
-
Positive control
- ICC/IF: HeLa cells. IHC-P: Lymphoma tissue.
-
General notes
This product is FOR RESEARCH USE ONLY. For commercial use, please contact partnerships@abcam.com.
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing the problem with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation.
One factor contributing to the crisis is the use of antibodies that are not suitable. This can lead to misleading results and the use of incorrect data informing project assumptions and direction. To help address this challenge, we have introduced an application and species grid on our primary antibody datasheets to make it easy to simplify identification of the right antibody for your needs.
Learn more here.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles. -
Storage buffer
pH: 7.60
Preservative: 0.1% Sodium azide
Constituents: PBS, 1% BSA -
Concentration information loading... -
Purity
Immunogen affinity purified -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab3642 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Tested applications are guaranteed to work and covered by our Abpromise guarantee.
Predicted to work for this combination of applications and species but not guaranteed.
Does not work for this combination of applications and species.
| Application | Species |
|---|---|
| ICC/IF |
Human
|
| Application | Abreviews | Notes |
|---|---|---|
| IHC-P |
1/25. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
|
|
| ICC/IF |
Use a concentration of 1 µg/ml.
|
| Notes |
|---|
|
IHC-P
1/25. Perform heat mediated antigen retrieval before commencing with IHC staining protocol. |
|
ICC/IF
Use a concentration of 1 µg/ml. |
Target
-
Relevance
The gene for CDK2NA generates several transcripts/proteins which differ from each other in their first exons. Three of these transcripts are generated by alternative splicing (isoform 1 a.k.a p16INK4A, isoform 2 and isoform 3 a.k.a p12), two of which are known to function as inhibitors of CDK4 kinase. One other transcript that is generated from this gene contains an alternate reading frame (ARF), with the first exon located 20kb upstream of the remainder of the gene(isoform 4 a.k.a. p14ARF, p19ARF, ARF). In spite of the structural and some functional differences, all the proteins encoded by the CDKN2A gene are involved in cell cycle G1 control. -
Cellular localization
Cytoplasmic and Nuclear -
Database links
- Entrez Gene: 1029 Human
- Omim: 600160 Human
- SwissProt: P42771 Human
- SwissProt: Q8N726 Human
- Unigene: 512599 Human
-
Alternative names
- ARF antibody
- CDK4 inhibitor p16 INK4 antibody
- CDK4I antibody
see all
Images
-
Immunocytochemistry/ Immunofluorescence - Anti-CDKN2A/p14ARF antibody (ab3642)
Confocal image showing nuclear staining increased after HeLa cells transfected with CDKN2A/p14ARF.
ICC/IF image of ab3642 stained HeLa cells. The cells were 4% paraformaldehyde fixed and then incubated in 0.1% trixtonX-100 to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with primary antibody ab3642 at a dilution of 1/250. An AlexaFluor®594 goat anti-mouse secondary IgG (ab150077) was used at a 1/1000 dilution. Anti-tubulin (ab7291) and an AlexaFluor®594 goat anti-mouse IgG (ab150120) were used as counterstains, both at a dilution of 1/1000. DAPI was used to stain the cell nuclei blue.
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CDKN2A/p14ARF antibody (ab3642)This image was kindly supplied as part of the review submitted by Joost van Galen. -
Immunocytochemistry/ Immunofluorescence - Anti-CDKN2A/p14ARF antibody (ab3642)ICC/IF image of ab3642 stained HeLa cells. The cells were 4% formaldehyde fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody ab3642 at 1µg/ml overnight at +4°C. The secondary antibody (green) was DyLight® 488 goat anti- rabbit (ab96899) IgG (H+L) used at a 1/250 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (15)
ab3642 has been referenced in 15 publications.
- Cui L et al. Overexpression of CCDC69 activates p14ARF/MDM2/p53 pathway and confers cisplatin sensitivity. J Ovarian Res 12:4 (2019). PubMed: 30651135
- Sargen MR et al. Biomarker discovery analysis: Alterations in p14, p16, p53, and BAP1 expression in nevi, cutaneous melanoma, and metastatic melanoma. Pigment Cell Melanoma Res 32:474-478 (2019). PubMed: 30672662
- Liang J et al. CDKN2A inhibits formation of homotypic cell-in-cell structures. Oncogenesis 7:50 (2018). PubMed: 29904067
- Xie H & Wang H PRL-3 promotes breast cancer progression by downregulating p14ARF-mediated p53 expression. Oncol Lett 15:2795-2800 (2018). PubMed: 29435006
- Yosef R et al. Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL. Nat Commun 7:11190 (2016). PubMed: 27048913